Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis

Abstract

Background Lung cancer is the most important cause of cancer-related deaths worldwide and the overall survival of patients with non-small cell lung cancer has not improved. Transforming growth factor beta or TGF-β is a polypeptide member of the transforming growth factor beta superfamily of cytokines, while far fewer clinical studies addressing the association between TGF-β expression and the disease prognosis have been reported up to now. Therefore, our meta-analysis aims to determine the prognostic significance of TGF-β expression in lung cancer patients. Methods PubMed, EMBASE, the Web of Science and China National Knowledge Infrastructure (CNKI) databases were searched for full-text literature citations. We applied the hazard ratio (HR) with 95% confidence interval (CI) as the appropriate summarized statistics. Q-test and I 2 statistic were used to estimate the level of heterogeneity. The publication bias was detected by Begg’s test and Egger’s test. Results Eight eligible studies involving 579 patients were selected for this meta-analysis. The combined HR for the eight eligible studies was 2.17 (95% CI: 1.71–2.77, P < 0.00001) and heterogeneity of overall prognosis was relatively low (I 2 = 14.2%, P = 0.319). We further undertook the subgroup analysis including assessment of the association between TGF-β expression and pathology of the lung cancer, treatment and quantity of sample in studies. All the results revealed that a significantly high TGF-β expression in patients was an indicator of poor survival. Neither Begg’s test nor Egger’s test found publication bias in any analysis. Conclusions The present evidence indicates that TGF-β expression can significantly predict the worse prognosis in patients with lung cancer. The findings of our meta-analysis may be confirmed in the future by the use of more updated review pooling and additional relevant investigations.

Identification of Novel Transcription Factor-microRNA-mRNA Co-regulatory Networks in Pulmonary Large-cell Neuroendocrine Carcinomas

“…However, the activation of TGF-β signaling pathway is suppressed in SCLC cells [59]. Recently, Li et al analyzed eight studies involving 579 patients with lung cancer and concluded that high TGF-β expression as an indicator of poor survival [60].…”

Meta-analysis of the prognostic significance of FOXC2 in various tumors

“… 20 In addition, several EMT-inducing factors, such as E-cadherin, transforming growth factor-β, and FOX proteins, could help predict prognosis in patients with cancer. 5 , 6 , 21 , 22 According to some previous studies, among these predictors, the FOX proteins, including FOXM1, FOXQ1, FOXF1, FOXC1, FOXA1/2, and FOXO3a, are involved in tumor metastasis by mediating EMT. 5 Indeed, the prognostic impact of FOXC2 has been well documented in different cancers.…”

TGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment

“…Although recognized as a tumor suppressor factor for healthy cells and early-stage cancer cells, in late-stage cancer TGF-β becomes the archetype of the tolerogenic tumor milieu, by primarily controlling the commitment and effector functions of immune cell subsets within the TME [ 102 , 103 ]. In this regard, TGF-β signaling represents a negative hallmark for many tumors and its activation has been linked with poor prognosis in colorectal [ 104 ] lung [ 105 ], breast [ 106 ] cancers, among others. Fundamentally, TGF-β can act by directly inhibiting anti-tumor immunity while sustaining the phenotype and function of pro-tumoral immune cells.…”